JP2019512242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512242A5 JP2019512242A5 JP2018548050A JP2018548050A JP2019512242A5 JP 2019512242 A5 JP2019512242 A5 JP 2019512242A5 JP 2018548050 A JP2018548050 A JP 2018548050A JP 2018548050 A JP2018548050 A JP 2018548050A JP 2019512242 A5 JP2019512242 A5 JP 2019512242A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- seq
- chain
- alpha
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000007487 gallbladder carcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308970P | 2016-03-16 | 2016-03-16 | |
| US62/308,970 | 2016-03-16 | ||
| GB1604494.3 | 2016-03-16 | ||
| GBGB1604494.3A GB201604494D0 (en) | 2016-03-16 | 2016-03-16 | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| PCT/EP2017/056289 WO2017158116A1 (en) | 2016-03-16 | 2017-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512242A JP2019512242A (ja) | 2019-05-16 |
| JP2019512242A5 true JP2019512242A5 (enExample) | 2019-06-20 |
| JP6929867B2 JP6929867B2 (ja) | 2021-09-01 |
Family
ID=55952419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548050A Expired - Fee Related JP6929867B2 (ja) | 2016-03-16 | 2017-03-16 | がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10537624B2 (enExample) |
| EP (1) | EP3430037B1 (enExample) |
| JP (1) | JP6929867B2 (enExample) |
| KR (1) | KR102266721B1 (enExample) |
| CN (1) | CN108884143A (enExample) |
| AU (1) | AU2017235069B2 (enExample) |
| BR (1) | BR112018067989A2 (enExample) |
| CA (1) | CA3017419A1 (enExample) |
| CR (1) | CR20180490A (enExample) |
| EA (1) | EA201891759A1 (enExample) |
| GB (1) | GB201604494D0 (enExample) |
| MA (2) | MA43328B2 (enExample) |
| MX (1) | MX2018011223A (enExample) |
| PE (1) | PE20190124A1 (enExample) |
| SG (1) | SG11201807590SA (enExample) |
| TW (1) | TWI788284B (enExample) |
| UA (1) | UA124532C2 (enExample) |
| WO (1) | WO2017158116A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221375T1 (hr) * | 2016-03-16 | 2023-01-06 | Immatics Biotechnologies Gmbh | Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| US11603519B2 (en) * | 2017-02-06 | 2023-03-14 | National Cancer Center Japan | T-cell receptor |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| SG11202007622SA (en) | 2018-02-11 | 2020-09-29 | Memorial Sloan Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
| BR112020016330A8 (pt) | 2018-02-12 | 2023-04-18 | Hutchinson Fred Cancer Res | Receptores de células t específicas a ciclina a1 e usos dos mesmos |
| JP7412006B2 (ja) * | 2018-03-14 | 2024-01-12 | メディジーン イミュノテラピーズ ゲーエムベーハー | 誘導性ｔ細胞レセプター及びその使用 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| CN112566698A (zh) * | 2018-04-05 | 2021-03-26 | 朱诺治疗学股份有限公司 | T细胞受体和表达该t细胞受体的工程化细胞 |
| EP3854802A4 (en) * | 2018-09-21 | 2022-10-12 | XLifeSc, Ltd. | HIGH AFFINE T-CELL RECEPTOR FOR RECOGNIZING AN AFP ANTIGEN |
| WO2020123388A1 (en) * | 2018-12-11 | 2020-06-18 | Board Of Regents, The University Of Texas System | Radiotherapies and uses thereof |
| KR102819623B1 (ko) * | 2018-12-20 | 2025-06-12 | 아바 라이프사이언스 게엠베하 | 생물학적 결합 분자를 선택하는 방법 |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| CN114245745A (zh) * | 2019-06-20 | 2022-03-25 | 纪念斯隆-凯特琳癌症中心 | 靶向pik3ca突变的t细胞受体及其用途 |
| CN110357953B (zh) * | 2019-07-17 | 2022-05-03 | 深圳市因诺转化医学研究院 | 识别人巨细胞病毒pp65抗原的TCR |
| US20220288118A1 (en) * | 2019-07-31 | 2022-09-15 | Forty Seven, Inc. | Depletion regimes for engineered t-cell or nk-cell therapy |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| KR20220078607A (ko) * | 2019-09-12 | 2022-06-10 | 티씨알2 테라퓨틱스 인크. | 융합 단백질들을 이용한 tcr 재프로그래밍을 위한 조성물 및 방법들 |
| JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2021259237A1 (en) * | 2020-06-22 | 2021-12-30 | Nanjing Legend Biotech Co., Ltd. | GENETIC ENGINEERING OF γδ T CELLS FOR IMMUNOTHERAPY |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| CR20230295A (es) | 2020-12-31 | 2023-07-27 | Immatics Us Inc | Polipéptidos cd8, composiciones y métodos de uso de estos |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| KR20250018168A (ko) | 2022-04-28 | 2025-02-04 | 이매틱스 유에스 인코포레이티드 | 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법 |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| AU2014271235B2 (en) * | 2008-10-01 | 2017-03-02 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
| TW201124530A (en) * | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| US9879065B2 (en) * | 2012-09-14 | 2018-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
-
2016
- 2016-03-16 GB GBGB1604494.3A patent/GB201604494D0/en not_active Ceased
-
2017
- 2017-03-16 TW TW106108697A patent/TWI788284B/zh not_active IP Right Cessation
- 2017-03-16 CA CA3017419A patent/CA3017419A1/en not_active Abandoned
- 2017-03-16 SG SG11201807590SA patent/SG11201807590SA/en unknown
- 2017-03-16 EP EP17710963.4A patent/EP3430037B1/en active Active
- 2017-03-16 JP JP2018548050A patent/JP6929867B2/ja not_active Expired - Fee Related
- 2017-03-16 PE PE2018001777A patent/PE20190124A1/es unknown
- 2017-03-16 AU AU2017235069A patent/AU2017235069B2/en not_active Ceased
- 2017-03-16 WO PCT/EP2017/056289 patent/WO2017158116A1/en not_active Ceased
- 2017-03-16 MX MX2018011223A patent/MX2018011223A/es unknown
- 2017-03-16 CR CR20180490A patent/CR20180490A/es unknown
- 2017-03-16 KR KR1020187029658A patent/KR102266721B1/ko not_active Expired - Fee Related
- 2017-03-16 BR BR112018067989-5A patent/BR112018067989A2/pt not_active IP Right Cessation
- 2017-03-16 CN CN201780017419.XA patent/CN108884143A/zh active Pending
- 2017-03-16 MA MA43328A patent/MA43328B2/fr unknown
- 2017-03-16 US US15/461,020 patent/US10537624B2/en active Active
- 2017-03-16 MA MA45309A patent/MA45309B1/fr unknown
- 2017-03-16 UA UAA201809121A patent/UA124532C2/uk unknown
- 2017-03-16 EA EA201891759A patent/EA201891759A1/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511936A5 (enExample) | ||
| US20220235113A1 (en) | TCR Libraries | |
| JP2020500523A5 (enExample) | ||
| US10538573B2 (en) | Transfected T-cells and T-cell receptors for use in immunotherapy against cancers | |
| US20210101956A1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| JP2016503295A5 (enExample) | ||
| FI3688027T3 (fi) | Mutatoidun p53:n tunnistavia t-solureseptoreita | |
| JP2014528714A5 (enExample) | ||
| FI3946621T3 (fi) | Mage a4 -t-solureptoreja | |
| HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
| JP2024544520A5 (enExample) | ||
| JP2023159112A5 (enExample) | ||
| JP2015506945A5 (enExample) | ||
| CA3001264A1 (en) | Pd-l1 binding polypeptide | |
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| JP2012531212A5 (enExample) | ||
| FI3515487T3 (fi) | Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja | |
| JP2018512145A5 (enExample) | ||
| JP2021511811A5 (enExample) | ||
| JP2016196468A5 (enExample) | ||
| JP2012100677A5 (enExample) | ||
| JP2014500002A5 (enExample) | ||
| JP2022548764A5 (enExample) | ||
| CN115867310A (zh) | 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物 | |
| HRP20221375T1 (hr) | Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka |